Torres Novas

Researchers are evaluating how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes T2D, lose weight. The purpose of this clinical study is to find out how safe and effective CagriSema is for body weight loss compared to semaglutide, a medicine already prescribed by doctors. This is a Phase 3 randomized trial lasting about 83 weeks. Participants will be randomly assigned to receive either one of two doses of CagriSema or semaglutide, all given once weekly by injection under the skin during a 72-week treatment period. CagriSema is a new medicine being tested, while semaglutide serves as an active comparator. The study compares these treatments for their effects on weight loss and related health measures. During the study, participants will have regular assessments including body weight, body mass index BMI, waist circumference, cholesterol levels, and blood sugar control measured by HbA1c. Researchers will also monitor physical function and quality of life through questionnaires. Safety is tracked by recording any adverse events up to 80 weeks. The main outcome is the change in body weight from the start of treatment to the end of the 72-week period.

Alport syndrome AS is a rare genetic disorder that affects the kidneys, hearing, and eyes due to changes in specific genes responsible for producing collagen. People with AS face a high risk of chronic kidney disease, where kidney function gradually worsens, often causing excess protein in the urine, called proteinuria. This study aims to evaluate how well BAY 3401016, a monoclonal antibody that blocks the protein Semaphorin 3A involved in kidney damage, works to slow kidney function loss in adults with rapidly progressing AS. Participants will receive either BAY 3401016 or a placebo once a week for 24 weeks, along with their usual background therapy if eligible. The trial is randomized and double-blind, meaning neither participants nor researchers know who receives the study drug or placebo. This is a Phase 2a study with an extension phase to further assess BAY 3401016s effects in adults aged 18 to 45 years. During the study, researchers will measure the urinary albumin creatinine ratio UACR over 16, 20, and 24 weeks of treatment to evaluate kidney function changes. Safety and tolerability of BAY 3401016 will also be monitored throughout the treatment and up to 90 days after the last dose. Participants will have regular assessments to track kidney health and side effects, with the total follow-up lasting beyond the treatment period.

Researchers are conducting a combined phase 2b and phase 3 study to evaluate the drug CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing dialysis. The study focuses on participants with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. The trial aims to find the best dose of CSL300 and then assess its effects on cardiovascular outcomes and safety compared to a placebo. The study is divided into two parts Part 1 phase 2b is a dose-finding phase where different doses of CSL300 are given intravenously to participants to determine the optimal dose versus placebo. Part 2 phase 3 evaluates the efficacy and safety of the selected CSL300 dose compared to placebo over approximately five years. All treatments are administered by intravenous infusion. Participants will be involved in regular assessments including blood tests to measure inflammation markers such as high-sensitivity C-reactive protein hs-CRP, cardiovascular events tracking, and monitoring for adverse events. The phase 2b portion includes up to 24 weeks of follow-up for dose evaluation, while the phase 3 portion monitors cardiovascular outcomes like heart attacks or cardiovascular death over about five years. Safety and drug levels in the blood will also be closely observed throughout the study.